These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31565009)

  • 21. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li C; Li X; Huang F; Yang J; Wu A; Wang L; Qin D; Zou W; Wu J
    Front Pharmacol; 2019; 10():829. PubMed ID: 31402863
    [No Abstract]   [Full Text] [Related]  

  • 23. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease.
    Lozano ML
    Rev Esp Enferm Dig; 2021 Feb; 113(2):136-140. PubMed ID: 33233913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists.
    Miller JB; Figueroa EJ; Haug RM; Shah NL
    Gastroenterol Hepatol (N Y); 2019 Jun; 15(6):326-332. PubMed ID: 31391802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Catastrophic antiphospholipid syndrome in an immune thrombocytopenia patient treated with avatrombopag.
    Van de Vondel S; Vandenbriele C; Gheysens G; Verhamme P; Janssens A
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100125. PubMed ID: 37065845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eltrombopag for use in children with immune thrombocytopenia.
    Kim TO; Despotovic J; Lambert MP
    Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB; Keating GM; Garnock-Jones KP
    Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia.
    Vishnu P; Aboulafia DM
    J Blood Med; 2016; 7():99-106. PubMed ID: 27307776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.
    Poordad F; Terrault NA; Alkhouri N; Tian W; Allen LF; Rabinovitz M
    Int J Hepatol; 2020; 2020():5421632. PubMed ID: 32047671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.
    Danish FI; Yasmin S
    Hepat Med; 2013; 5():17-30. PubMed ID: 24696622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
    Maitland HS
    Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.